First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study
Open Access
- 1 October 2003
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 5 (5), R114-R120
- https://doi.org/10.1186/bcr618
Abstract
The nadir value of the absolute neutrophil count (ANC) in the first cycle of chemotherapy is an effective predictor of subsequent neutropenic events. This study was designed to validate an earlier published study based on a retrospective data analysis from a prospective randomized clinical trial. The original published model was applied to a trial of 143 patients to cross-validate the model. We also tested the specification of the model on our data by using a logistic regression model with several variables, including first-cycle nadir ANC, age, menopausal status, hormone-receptor status, previous radiotherapy, and first-cycle decrease in hemoglobin concentration. Patients received fluorouracil, doxorubicin, and cyclophosphamide every 21 or 28 days for six cycles without hematopoietic support from colony-stimulating factor. In the cross-validation analysis, the original model successfully classified patients by risk of neutropenic events (C = 0.78). When the model specification was tested, first-cycle nadir ANC was the sole significant (P < 0.0001) predictor of neutropenic events and the model had a good predictive power (C = 0.78). The estimated relative risk of 4.8 did not differ from the risk cited in the original model (P = 0.91). A significantly higher percentage of our patients with a low first-cycle nadir ANC of 0.25 × 109/liter or less experienced febrile neutropenia (30% versus 10%, P = 0.04) and received at least 85% of the planned dose intensity (55% versus 32%, P = 0.05). The original risk model used to predict neutropenic events was validated by our study. This information can be used to target high-risk patients for prophylactic treatment with filgrastim (recombinant methionyl human granulocyte colony-stimulating factor) in chemotherapy cycles 2 to 6.Keywords
This publication has 11 references indexed in Scilit:
- Targeted filgrastim support in patients with early-stage breast carcinomaCancer, 2003
- Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factorsSupportive Care in Cancer, 2003
- Delivering adjuvant chemotherapy to women with early-stage breast carcinomaCancer, 2001
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.Journal of Clinical Oncology, 1998
- Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer.Journal of Clinical Oncology, 1998
- Dose Intensity of Standard Adjuvant CMF with Granulocyte Colony-Stimulating Factor for Premenopausal Patients with Node-Positive Breast CancerOncology, 1996
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomyAmerican Journal Of Medicine, 1987